New technology for pathogen detection driven by lasers

February 14, 2020

WEST LAFAYETTE, Ind. - Researchers at Purdue University have been working to develop new technologies to help stop the spread of foodborne illnesses, which kill 3,000 people a year, by detecting them more efficiently. They have developed a lanthanide-based assay coupled with a laser that can be used to detect toxins and pathogenic E. coli in food samples, water and a variety of industrial materials.

The two key features of the new technology are the incorporation of lanthanides and simple lateral flow paper-based assays. The Purdue team created a method for combining different heavy metals that when linked to antibodies can detect multiple agents in a single analysis. The Purdue team's work is published in the January edition of Analytical and Bioanalytical Chemistry.

"Our goal was to incorporate easily detectable elements into a paper-based assay which is low-cost and effective," said J. Paul Robinson, the SVM Professor of Cytomics in Purdue's College of Veterinary Medicine and a professor of biomedical engineering in Purdue's College of Engineering. "Designing a technology that is both low-cost but also accurate and can detect multiple antigens simultaneously was a critical factor in our decision to work on this problem."

The innovators worked with the Purdue Research Foundation Office of Technology Commercialization to patent the technology in the United States and in Europe. They are looking for partners. For more information, contact Dipak Narula of OTC at dnarula@prf.org and reference track code 2019-ROBI-68413.

"We are very excited about the acceptance of the intellectual property as this will enhance the possibility of finding commercial partners," Robinson said. "The potential for moving this to handheld, field deployable use is something we see in the future."

The group is evaluating the potential for fully portable use that would allow field use in virtually any environment.

The approach uses a high-powered laser pulse to obliterate a sample, while simultaneously collecting the spectral signature of the resultant emission. These signals are then compared with a database that translates the signals into an identification of the toxin or pathogen.

The work presented in this paper shows the proof of principle and is the basis for significant expansion of the studies. What makes the technology effective is the linking of antibodies to different heavy metal tags. This creates a unique fingerprint of atomic signatures that can be used to determine if any particular pathogen of interest in present in a sample.
-end-
The U.S. Department of Agriculture Agricultural Research Service (ARS) and Center for Food Safety Engineering (CFSE) provided funding for the technology research in addition to Hatch Funds, which support agricultural research at land-grant institutions across the U.S.

About Purdue Research Foundation Office of Technology Commercialization

The Purdue Research Foundation Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university's academic activities through commercializing, licensing and protecting Purdue intellectual property. The office recently moved into the Convergence Center for Innovation and Collaboration in Discovery Park District, located on the west side of the Purdue campus. The office is managed by the Purdue Research Foundation, which received the 2019 Innovation and Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University. Contact otcip@prf.org for more information.

Writer: Chris Adam, 765-588-3341, cladam@prf.org

Source: J. Paul Robinson, wombat@purdue.edu

Purdue University

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.